Post by Halozyme, Inc.

We are pleased to share a recent article in Drug Delivery and Translational Research highlighting work on #subcutaneous delivery of antibody-drug conjugates (ADCs): “Enhanced subcutaneous delivery of antibody drug conjugates with recombinant human hyaluronidase PH20: pharmacokinetics and tolerability in minipigs.” Congratulations to the full author team, including: Ryan Nolan, Robert Connor, Marie Printz, Yan Wang, Tara Nekoroski, Limin Liu, Chris Wahl, Charles Theuer, and David Kang. This preclinical study evaluated the pharmacokinetics and local tolerability of two marketed ADCs administered subcutaneously, with and without recombinant human hyaluronidase PH20 (rHuPH20), compared to IV dosing. Key observations included: - Improved injection performance and reduced local effects (e.g., swelling, back-leakage) with rHuPH20 - Increased systemic exposure relative to SC dosing alone, while maintaining lower peak concentrations compared to IV - Reduced local retention in skin tissue, suggesting enhanced dispersion and absorption - These findings contribute to the growing body of research exploring approaches to enable subcutaneous delivery of complex biologics, including ADCs. Read the full article here: https://lnkd.in/gMFCXKQ6